Healthcare / Drug Manufacturers - Specialty & GenericTaiwan
$41.90
+1.10 (+2.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-389.9M · quality 56.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.0B
P/E
46.6x
↑EV/EBITDA
16.5x
↑ROE
2.0%
↑Gross Margin
26.1%
↓Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+14.3%
FCF CAGR
—
FCF margin
-29.0%
FCF / Net income
-3.63x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.34B · net income $107.4M · FCF $-389.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.34B | $1.34B | $1.52B | $1.20B | $899.7M |
| Net Income | $107.4M | $107.4M | $534.7M | $294.7M | $308.8M |
| EBITDA | $360.1M | $360.1M | $886.2M | $515.8M | $479.5M |
| EPS | — | — | 4.46 | 2.69 | 2.87 |
| Gross Margin | 26.1% | 26.1% | 27.0% | 29.1% | 32.4% |
| Operating Margin | 11.6% | 11.6% | 13.0% | 13.3% | 13.2% |
| Net Margin | 8.0% | 8.0% | 35.1% | 24.5% | 34.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.18 | 0.18 | 0.18 | 0.20 | 0.15 |
| Current Ratio | 1.05 | 1.05 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-389.9M | $-389.9M | $-86.1M | $-813.6M | $-871.0M |
| Returns | |||||
| ROE | 2.0% | 2.0% | 9.8% | 5.8% | 8.5% |
| Valuation | |||||
| P/E | 46.56 | 46.56 | 20.27 | 37.17 | 28.97 |
| EV/EBITDA | 16.48 | 16.48 | 12.70 | 21.45 | 19.44 |
| P/B | 0.93 | 0.93 | 1.98 | 2.15 | 2.46 |
| Growth & Yield | |||||
| Revenue Growth | -11.8% | -11.8% | 26.5% | 33.8% | — |
| EPS Growth | — | — | 65.8% | -6.3% | — |
| Dividend Yield | 3.6% | 3.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-37.6%
Start / end P/E
n/dx → n/dx
EPS bridge
4.46 → n/d
Residual
-41.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.